3 research outputs found
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell
(DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was
developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety
of switching from intravenous to subcutaneous administration of rituximab
during first-line induction/maintenance for DLBCL or FL, focusing on
ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients
received subcutaneous rituximab plus standard induction chemotherapy for
DLBCL or FL for 4–7 cycles, and/or every 2 months maintenance
monotherapy for FL for 6–12 cycles. The study included 140 patients:
DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced
adverse events, reaching grade ≥3 in 38 6% and were serious in 30 0%.
AARs occurred in 48 6%, mostly (84 9%) at the injection site, with only
2 1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69 6%. After a median follow-up of
33 5 months, median disease-/event-/progression-free and overall survivals
were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a
good quality-of-life perception at induction/maintenance end. Therefore,
switching to subcutaneous rituximab showed no new safety issues and
maintained efficacy with improved satisfaction and quality of life
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
[EN] Monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM) are plasma cell disorders with a risk of progression of approximately 1% and 10% per year, respectively. We have previously shown that the proportion of bone marrow (BM) aberrant plasma cells (aPCs) within the BMPC compartment (aPC/BMPC) as assessed by flow cytometry (FC) contributes to differential diagnosis between MGUS and multiple myloma (MM). The goal of the present study was to investigate this parameter as a marker for risk of progression in MGUS (n = 407) and SMM (n = 93). Patients with a marked predominance of aPCs/BMPC (> or = 95%) at diagnosis displayed a significantly higher risk of progression both in MGUS and SMM (P or = 95%) as the most important independent variable, together with DNA aneuploidy and immunoparesis, for MGUS and SMM, respectively. Using these independent variables, we have identified 3 risk categories in MGUS (PFS at 5 years of 2%, 10%, and 46%, respectively; P< .001) and SMM patients (PFS at 5 years of 4%, 46%, and 72%, respectively; P < .001). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell
(DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was
developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety
of switching from intravenous to subcutaneous administration of rituximab
during first-line induction/maintenance for DLBCL or FL, focusing on
ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients
received subcutaneous rituximab plus standard induction chemotherapy for
DLBCL or FL for 4–7 cycles, and/or every 2 months maintenance
monotherapy for FL for 6–12 cycles. The study included 140 patients:
DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced
adverse events, reaching grade ≥3 in 38 6% and were serious in 30 0%.
AARs occurred in 48 6%, mostly (84 9%) at the injection site, with only
2 1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69 6%. After a median follow-up of
33 5 months, median disease-/event-/progression-free and overall survivals
were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a
good quality-of-life perception at induction/maintenance end. Therefore,
switching to subcutaneous rituximab showed no new safety issues and
maintained efficacy with improved satisfaction and quality of life